Next Article in Journal
Lights and Shadows in Immuno-Oncology Drug Development
Next Article in Special Issue
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
Previous Article in Journal
Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Editorial

Why Target Innate Immune Cells in Cancers?

by 1,2
1
Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, 31037 Toulouse, France
2
Université Toulouse III Paul-Sabatier, 31400 Toulouse, France 3. ERL 5294 CNRS, 31037 Toulouse, France
Cancers 2021, 13(4), 690; https://doi.org/10.3390/cancers13040690
Received: 28 January 2021 / Accepted: 5 February 2021 / Published: 9 February 2021
(This article belongs to the Special Issue Targeting the Innate Immune Cells in Cancers)
Note: In lieu of an abstract, this is an excerpt from the first page.

The immune system is a smart way to fight cancer, with its precise targeting of cancer cells sparing healthy cells [...] View Full-Text
MDPI and ACS Style

Poupot, M. Why Target Innate Immune Cells in Cancers? Cancers 2021, 13, 690. https://doi.org/10.3390/cancers13040690

AMA Style

Poupot M. Why Target Innate Immune Cells in Cancers? Cancers. 2021; 13(4):690. https://doi.org/10.3390/cancers13040690

Chicago/Turabian Style

Poupot, Mary. 2021. "Why Target Innate Immune Cells in Cancers?" Cancers 13, no. 4: 690. https://doi.org/10.3390/cancers13040690

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop